Literature DB >> 18451228

Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies) in bead-based ELISA.

Nathalie Scholler1, Kimberly A Lowe, Lindsay A Bergan, Archana V Kampani, Vivian Ng, Robin M Forrest, Jason D Thorpe, Jenny A Gross, Barbara M Garvik, Ronny Drapkin, Garnet L Anderson, Nicole Urban.   

Abstract

PURPOSE: To measure circulating antigens, sandwich ELISA assays require two complementary affinity reagents. Mouse monoclonal antibodies (mAb) and polyclonal antibodies (pAb) are commonly used, but because their production is lengthy and costly, recombinant antibodies are emerging as an attractive alternative. EXPERIMENTAL
DESIGN: We developed a new class of recombinant antibodies called biobodies (Bb) and compared them to mAb for use in serodiagnosis. Bbs were secreted biotinylated in vivo by diploid yeast and used as affinity reagents after Ni purification. Bead-based assays for HE4 and mesothelin were developed using Bbs in combination with pAbs (Bb/pAb assays). To assess precision, reproducibility studies were done using four runs of 16 replicates at six analyte levels for each marker. Pearson correlations and receiver-operator characteristic analyses were done in 214 patient serum samples to directly compare the Bb/pAb assays to mAb assays. Diagnostic performance of the Bb/pAb assay was further assessed in an expanded set of 336 ovarian cancer cases and controls.
RESULTS: On average across analyte levels, Bb/pAb assays yielded within-run and between-run coefficients of variations of 11.7 and 23.8, respectively, for HE4 and 14.0 and 14.5, respectively, for mesothelin. In the subset (n = 214), Pearson correlations of 0.95 for HE4 and 0.92 for mesothelin were observed between mAb and Bb/pAb assays. The area under the curves for the mAb and Bb/pAb assays were not significantly different for HE4 (0.88 and 0.84, respectively; P = 0.20) or mesothelin (0.74 and 0.72, respectively; P = 0.38).
CONCLUSION: Yeast-secreted Bbs can be used reliably in cost-effective yet highly sensitive bead-based assays for use in large validation studies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18451228      PMCID: PMC2744596          DOI: 10.1158/1078-0432.CCR-07-1442

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  27 in total

1.  Changes in cancer worry associated with participation in ovarian cancer screening.

Authors:  M Robyn Andersen; Charles W Drescher; Yingye Zheng; Deborah J Bowen; Susan Wilson; Alicia Young; Martin McIntosh; Barry S Mahony; Kimberly A Lowe; Nicole Urban
Journal:  Psychooncology       Date:  2007-09       Impact factor: 3.894

2.  Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas.

Authors:  M Schummer; W V Ng; R E Bumgarner; P S Nelson; B Schummer; D W Bednarski; L Hassell; R L Baldwin; B Y Karlan; L Hood
Journal:  Gene       Date:  1999-10-01       Impact factor: 3.688

3.  The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma.

Authors:  Ingegerd Hellström; John Raycraft; Martha Hayden-Ledbetter; Jeffrey A Ledbetter; Michèl Schummer; Martin McIntosh; Charles Drescher; Nicole Urban; Karl Erik Hellström
Journal:  Cancer Res       Date:  2003-07-01       Impact factor: 12.701

4.  Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library.

Authors:  Michael J Feldhaus; Robert W Siegel; Lee K Opresko; James R Coleman; Jane M Weaver Feldhaus; Yik A Yeung; Jennifer R Cochran; Peter Heinzelman; David Colby; Jeffrey Swers; Christilyn Graff; H Steven Wiley; K Dane Wittrup
Journal:  Nat Biotechnol       Date:  2003-01-21       Impact factor: 54.908

5.  Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma.

Authors:  M W McIntosh; C Drescher; B Karlan; N Scholler; N Urban; K E Hellstrom; I Hellstrom
Journal:  Gynecol Oncol       Date:  2004-10       Impact factor: 5.482

6.  Expression of candidate tumor markers in ovarian carcinoma and benign ovary: evidence for a link between epithelial phenotype and neoplasia.

Authors:  Ronny Drapkin; Christopher P Crum; Jonathan L Hecht
Journal:  Hum Pathol       Date:  2004-08       Impact factor: 3.466

7.  Compliance of average- and intermediate-risk women to semiannual ovarian cancer screening.

Authors:  Charles W Drescher; Judy Nelson; Sue Peacock; M Robyn Andersen; Martin W McIntosh; Nicole Urban
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2004-04       Impact factor: 4.254

8.  GPI-specific phospholipase D mRNA expression in tumor cells of different malignancy.

Authors:  H Xiaotong; Melanie-Jane Hannocks; Ian Hampson; Georg Brunner
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

9.  Mesothelin-family proteins and diagnosis of mesothelioma.

Authors:  Bruce W S Robinson; Jenette Creaney; Richard Lake; Anna Nowak; A William Musk; Nick de Klerk; Pernilla Winzell; Karl Erik Hellstrom; Ingegerd Hellstrom
Journal:  Lancet       Date:  2003-11-15       Impact factor: 79.321

Review 10.  Ovarian cancer screening.

Authors:  Nicole Urban; Martin W McIntosh; Marin Andersen; Beth Y Karlan
Journal:  Hematol Oncol Clin North Am       Date:  2003-08       Impact factor: 3.722

View more
  17 in total

1.  Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer.

Authors:  Eleftheria Kalogera; Nathalie Scholler; Cecelia Powless; Amy Weaver; Ronny Drapkin; Jinping Li; Shi-Wen Jiang; Karl Podratz; Nicole Urban; Sean C Dowdy
Journal:  Gynecol Oncol       Date:  2011-10-28       Impact factor: 5.482

2.  fTwo novel biomarkers, mesothelin and HE4, for diagnosis of ovarian carcinoma.

Authors:  Ingegerd Hellstrom; Karl Erik Hellstrom
Journal:  Expert Opin Med Diagn       Date:  2011-05-01

3.  Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens.

Authors:  Daniel W Cramer; Robert C Bast; Christine D Berg; Eleftherios P Diamandis; Andrew K Godwin; Patricia Hartge; Anna E Lokshin; Karen H Lu; Martin W McIntosh; Gil Mor; Christos Patriotis; Paul F Pinsky; Mark D Thornquist; Nathalie Scholler; Steven J Skates; Patrick M Sluss; Sudhir Srivastava; David C Ward; Zhen Zhang; Claire S Zhu; Nicole Urban
Journal:  Cancer Prev Res (Phila)       Date:  2011-03

4.  Rapid isolation of high-affinity human antibodies against the tumor vascular marker Endosialin/TEM1, using a paired yeast-display/secretory scFv library platform.

Authors:  Aizhi Zhao; Selene Nunez-Cruz; Chunsheng Li; George Coukos; Don L Siegel; Nathalie Scholler
Journal:  J Immunol Methods       Date:  2010-09-15       Impact factor: 2.303

5.  Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125.

Authors:  Michèl Schummer; Charles Drescher; Robin Forrest; Shirley Gough; Jason Thorpe; Ingegerd Hellström; Karl Erik Hellström; Nicole Urban
Journal:  Gynecol Oncol       Date:  2011-12-07       Impact factor: 5.482

6.  Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer.

Authors:  M Robyn Andersen; Barbara A Goff; Kimberly A Lowe; Nathalie Scholler; Lindsay Bergan; Charles W Drescher; Pamela Paley; Nicole Urban
Journal:  Gynecol Oncol       Date:  2009-11-28       Impact factor: 5.482

7.  Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer.

Authors:  Kimberly A Lowe; Chirag Shah; Erin Wallace; Garnet Anderson; Pamela Paley; Martin McIntosh; M Robyn Andersen; Nathalie Scholler; Lindsay Bergan; Jason Thorpe; Nicole Urban; Charles W Drescher
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-09       Impact factor: 4.254

8.  Human epididymis protein 4 expression positively correlated with miR-21 and served as a prognostic indicator in ovarian cancer.

Authors:  Yong Chen; Qingquan Chen; Qicai Liu; Feng Gao
Journal:  Tumour Biol       Date:  2016-01-05

9.  Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125.

Authors:  Chirag A Shah; Kimberly A Lowe; Pamela Paley; Erin Wallace; Garnet L Anderson; Martin W McIntosh; M Robyn Andersen; Nathalie Scholler; Lindsay A Bergan; Jason D Thorpe; Nicole Urban; Charles W Drescher
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-05       Impact factor: 4.254

10.  Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study.

Authors:  Garnet L Anderson; Martin McIntosh; Lieling Wu; Matt Barnett; Gary Goodman; Jason D Thorpe; Lindsay Bergan; Mark D Thornquist; Nathalie Scholler; Nam Kim; Kathy O'Briant; Charles Drescher; Nicole Urban
Journal:  J Natl Cancer Inst       Date:  2009-12-30       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.